89,704 Shares in Prothena Corporation plc $PRTA Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. acquired a new stake in Prothena Corporation plc (NASDAQ:PRTA) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 89,704 shares of the biotechnology company’s stock, valued at approximately $876,000. Assenagon Asset Management S.A. owned about 0.17% of Prothena as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Armistice Capital LLC increased its stake in shares of Prothena by 1.8% in the second quarter. Armistice Capital LLC now owns 2,236,000 shares of the biotechnology company’s stock worth $13,573,000 after buying an additional 40,000 shares during the period. Siren L.L.C. grew its holdings in Prothena by 16.7% in the 1st quarter. Siren L.L.C. now owns 1,283,555 shares of the biotechnology company’s stock worth $15,884,000 after acquiring an additional 183,715 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Prothena by 116.2% in the second quarter. Federated Hermes Inc. now owns 1,181,087 shares of the biotechnology company’s stock valued at $7,169,000 after acquiring an additional 634,832 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Prothena in the second quarter valued at about $6,176,000. Finally, Rangeley Capital LLC bought a new position in shares of Prothena during the second quarter valued at about $4,342,000. Institutional investors own 97.08% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on PRTA shares. Royal Bank Of Canada raised their target price on Prothena from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Friday, November 7th. UBS Group set a $36.00 price objective on Prothena in a report on Tuesday, October 28th. HC Wainwright boosted their target price on Prothena from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Citigroup restated a “market outperform” rating on shares of Prothena in a report on Monday, December 1st. Finally, Citizens Jmp raised their price target on Prothena from $11.00 to $19.00 and gave the stock a “market outperform” rating in a research note on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $25.60.

Prothena Trading Up 2.5%

Shares of Prothena stock opened at $9.73 on Thursday. Prothena Corporation plc has a 12 month low of $4.32 and a 12 month high of $16.67. The firm has a market capitalization of $523.55 million, a P/E ratio of -1.86 and a beta of -0.10. The business has a fifty day simple moving average of $10.25 and a two-hundred day simple moving average of $8.54.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). The business had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $6.64 million. Prothena had a negative net margin of 2,379.59% and a negative return on equity of 65.89%. Analysts predict that Prothena Corporation plc will post -4.04 earnings per share for the current year.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.